

16 September 2022

Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")

Investor Presentation

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class drugs in the high value and high growth oncology segment, is pleased to announce that Executive Chairman Stephen West and CEO Ajan Reginald will give a live presentation following completion of the **Acquisition of Oncogeni** via the Investor Meet Company platform on **Thursday 22 September at 2.00pm BST**.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and can arrange to meet ROQUEFORT THERAPEUTICS via:

<https://www.investormeetcompany.com/roquefort-therapeutics-plc/register-investor>

Investors who already follow **ROQUEFORT THERAPEUTICS PLC** on the Investor Meet Company platform will automatically be invited.

ENDS

Enquiries:

Roquefort Therapeutics plc

Stephen West (Chairman) / Ajan Reginald
(CEO)

+44 (0)20 3290
9339

Hybridan LLP (Joint Broker)

Claire Louise Noyce

+44 (0)203 764
2341

Optiva Securities Limited (Joint Broker)

Christian Dennis

+44 (0)20 3411
1881

Buchanan (Public Relations)

Ben Romney / Jamie Hooper / George Beale

+44 (0)20 7466
5000

LEI: 254900P4SISIWOR9RH34

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.

Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lynamid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.

Roquefort Therapeutics' portfolio consists of four fully funded, novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of four best-in-class medicines consists of:

- Midkine antibodies with significant *in vivo* efficacy and toxicology studies;
- Midkine RNA therapeutics with novel anti-cancer gene editing action;
- MK cell therapy with direct and NK-mediated anti-cancer action; and
- siRNA targeting novel STAT-6 target in solid tumours showing significant *in vivo* efficacy.

For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on Twitter.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an

orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAUVONRUUUKAAR

Anonymous (not verified)

Investor Presentation

32967999

A

Fri, 09/16/2022 - 08:00

LSE RNS

Company Announcement - General

ROQ